Cameron Noland

Dr. Cameron Noland

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MKMarc Kschonsak
Marc Kschonsak
HCHan Chow Chua
Han Chow Chua
CWClaudia Weidling
Claudia Weidling
NCNourdine Chakouri
Nourdine Chakouri
CNCameron Noland
Cameron Noland
JPJian Payandeh
Jian Payandeh

14 May 2020 in eLife
Verified
Journal Article
Open access
GHGrace E Hamilton
Grace E Hamilton
LHLuke A Helgeson
Luke A Helgeson
CNCameron Noland
Cameron Noland
CACharles L. Asbury
Charles L. Asbury
YDYoana N Dimitrova
Yoana N Dimitrova
TDTrisha N Davis
Trisha N Davis
Partitioning duplicated chromosomes equally between daughter cells is a microtubule-mediated process essential to eukaryotic life. A multi-protein machine, the kinetochore, drives chromosome segregation by coupling the chromosomes to dynamic microtubule tips, even as the tips grow and shrink through the gain and loss of subunits. The kinetochore must harness, transmit, and sense mitotic forces, as a lack of tension signals incorrect chromosome-microtubule attachment and precipitates error correction mechanisms. But though the field has arrived at a ‘parts list’ of dozens of kinetochore proteins organized into subcomplexes, the path of force transmission through these components has remained unclear. Here we report reconstitution of functional Saccharomyces cerevisiae kinetochore assemblies from recombinantly expressed proteins. The reconstituted kinetochores are capable of self-assembling in vitro, coupling centromeric nucleosomes to dynamic microtubules, and withstanding mitotically relevant forces. They reveal two distinct pathways of force transmission and Ndc80c recruitment.

1 February 2016 in SLAS Technology
Verified
Journal Article
Open access
PWPing Wu
Ping Wu
CNCameron Noland
Cameron Noland
MUMark Ultsch
Mark Ultsch
BEBonnie Edwards
Bonnie Edwards
DHDavid Harris
David Harris
SHSeth F. Harris
Seth F. Harris
Acoustic droplet ejection (ADE) enables crystallization experiments at the low-nanoliter scale, resulting in rapid vapor diffusion equilibration dynamics and efficient reagent usage in the empirical discovery of structure-enabling protein crystallization conditions. We extend our validation of this technology applied to the diverse physicochemical property space of aqueous crystallization reagents where dynamic fluid analysis coupled to ADE aids in accurate and precise dispensations. Addition of crystallization seed stocks, chemical additives, or small-molecule ligands effectively modulates crystallization, and we here provide examples in optimization of crystal morphology and diffraction quality by the acoustic delivery of ultra-small volumes of these cofactors. Additional applications are discussed, including set up of in situ proteolysis and alternate geometries of crystallization that leverage the small scale afforded by acoustic delivery. Finally, we describe parameters of a system of automation in which the acoustic liquid handler is integrated with a robotic arm, plate centrifuge, peeler, sealer, and stacks, which allows unattended high-throughput crystallization experimentation.

5 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MJMaru Jaime-Garza
Maru Jaime-Garza
AWAndrew Waight
Andrew Waight
MHManish Hudlikar
Manish Hudlikar
MEMichael J. Eddins
Michael J. Eddins
ERElnaz S. Rasti
Elnaz S. Rasti
CNCameron Noland
Cameron Noland
Background/Objectives: Antibody–Drug Conjugates (ADCs) have rapidly evolved from early, rudimentary conjugates to highly targeted and precisely engineered molecules. Despite notable clinical successes, ADCs continue to face significant challenges, including aggregation and high hydrophobicity driven by high drug-to-antibody ratios (DARs), premature payload release, dose-limiting toxicities, and suboptimal pharmacokinetics. While site-specific linker–payload conjugation has improved ADC homogeneity and stability, the structural basis of antibody–linker interactions at specific sites remains underexplored. Methods: In this work, we present the crystal structures of trastuzumab Fab and Fc domains site-specifically conjugated with a cleavable linker–payload. Results: Our findings suggest that pockets within both Fab and Fc regions may interact with and shield the linker portion of the conjugate. Conclusions: These insights highlight the previously underappreciated potential of structure-based design to drive the optimization of ADC linker chemistry and facilitate the co-design of bespoke linker–payloads tailored to individual antibody conjugation sites.

22 October 2025 in bioRxiv
Verified
Preprint
Open access
CPCarla P. Perez
Carla P. Perez
NDNicole V. DelRosso
Nicole V. DelRosso
CNCameron Noland
Cameron Noland
UPUdit Parekh
Udit Parekh
CCChristian A. Choe
Christian A. Choe
PHPo-Ssu Huang
Po-Ssu Huang
Protein-protein interactions underpin most cellular interactions, and engineered binders present powerful tools for probing biology and developing novel therapeutics. One bottleneck in binder generation is the scalable, quantitative characterization of these interactions. We present ADAPT-M ( A ffinity D etermination by A daptation of P ro T ein binders for M icrofluidics), a streamlined workflow that connects yeast surface display (YSD) with in vitro affinity and kinetic measurements using the high-throughput STAMMPPING microfluidic platform. ADAPT-M quantifies K d s and dissociation kinetic parameters for hundreds of enriched protein variants in under one week without requiring hands-on protein purification. We applied ADAPT-M to a computationally designed library targeting the SARS-CoV-2 Omicron BA.1 receptor binding domain, successfully recovering and measuring K d s for most highly enriched YSD variants. Measurements correlate strongly with biolayer interferometry and yeast titration assays. ADAPT-M further enabled selection of lead candidates for structural and mutational analysis, which revealed designed paratopes were preserved despite binding to off-target epitopes. By bridging YSD screening and in vitro validation, ADAPT-M accelerates protein binder discovery and supports data-driven protein engineering.

5 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JDJingyu Diao
Jingyu Diao
RKRie Komura
Rie Komura
TSTatsuya Sano
Tatsuya Sano
HPHomer Pantua
Homer Pantua
KSKelly M. Storek
Kelly M. Storek
SKSharookh B. Kapadia
Sharookh B. Kapadia
Lipoprotein diacylglyceryl transferase (Lgt) catalyzes the first step in the biogenesis of Gram-negative bacterial lipoproteins which play crucial roles in bacterial growth and pathogenesis. We demonstrate that Lgt depletion in a clinical uropathogenic Escherichia coli strain leads to permeabilization of the outer membrane and increased sensitivity to serum killing and antibiotics. Importantly, we identify the first ever described Lgt inhibitors that potently inhibit Lgt biochemical activity in vitro and are bactericidal against wild-type Acinetobacter baumannii and E. coli strains. Unlike inhibition of other steps in lipoprotein biosynthesis, deletion of the major outer membrane lipoprotein, lpp , is not sufficient to rescue growth after Lgt depletion or provide resistance to Lgt inhibitors. Our data validate Lgt as a novel druggable antibacterial target and suggest that inhibition of Lgt may not be sensitive to one of the most common resistance mechanisms that invalidate inhibitors of downstream steps of bacterial lipoprotein biosynthesis and transport.